Seizure medications, formally called antiseizure or antiepileptic drugs, work by calming overactive electrical signaling in the brain. More than two dozen are available, and most people with epilepsy can achieve meaningful seizure control with them. But roughly a third of patients on older drugs end up switching or adding medications because of side effects they cannot tolerate, and finding the right match often takes trial and adjustment.1PubMed Central. Efficacy and tolerability of antiseizure drugs The landscape of options has expanded dramatically over the past three decades, and understanding the differences between these drugs matters for anyone managing seizures or caring for someone who does.
How Seizure Medications Calm the Brain
Seizures happen when groups of neurons fire in uncontrolled bursts. Medications interrupt that process in a few distinct ways. One major group strengthens the brain’s natural braking system by boosting the activity of a chemical messenger called GABA, which tells neurons to slow down. Barbiturates and benzodiazepines both work through this pathway, though they do so by acting on different parts of the same receptor.2PubMed. Mechanisms of action of antiepileptic drugs
A second group works by blocking ion channels, the tiny gates in nerve cell membranes that allow electrically charged particles in and out. Phenytoin, carbamazepine, and lamotrigine all target sodium channels, preventing the rapid-fire electrical discharges that spread a seizure. Ethosuximide takes a different angle, blocking a type of calcium channel that is especially active in a brain region called the thalamus, which makes it useful for absence seizures specifically.3PubMed. Antiepileptic drug mechanisms of action Many newer drugs act on more than one of these pathways simultaneously, or work through mechanisms that researchers are still piecing together.
Older Versus Newer Drugs
The field loosely divides seizure medications into generations. The first-generation drugs, developed before the 1980s, include phenobarbital, phenytoin, carbamazepine, and valproate. They are effective, widely available, and inexpensive, but they come with a heavier side-effect burden. Over the past three decades, roughly 20 newer drugs have entered clinical use, including lamotrigine, levetiracetam, topiramate, oxcarbazepine, zonisamide, and lacosamide, among others.4PubMed Central. Efficacy and tolerability of antiseizure drugs
In general, these newer agents are better tolerated and have safer profiles than the older ones.5PubMed Central. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? That does not mean they are always more effective at stopping seizures. Head-to-head comparisons often find similar rates of seizure control across generations. The advantage of newer drugs tends to show up in fewer interactions with other medications, less impact on the liver, and side effects that are easier to manage day to day. Still, first-generation drugs remain the backbone of treatment in many parts of the world, partly because of cost and partly because they work well for many seizure types.
Matching the Drug to the Seizure Type
Not all seizures are the same, and the wrong medication can sometimes make things worse. A striking example involves carbamazepine, a sodium-channel blocker often used for focal seizures. Research has shown that carbamazepine can actually aggravate absence seizures, a type of generalized seizure where a person briefly zones out. A study using a mouse model of a genetic epilepsy found that carbamazepine selectively suppressed the tonic (steady) firing of certain inhibitory neurons in the thalamus without affecting their burst firing, disrupting the balance that keeps absence seizures in check. In those mice, carbamazepine treatment increased both seizure frequency and duration.6PubMed Central. Actions of the antiseizure drug carbamazepine in the thalamic reticular nucleus: Potential mechanism of aggravating absence seizures
This is why diagnosis matters so much before a prescription is written. Broad-spectrum drugs like valproate and lamotrigine can treat multiple seizure types, while narrow-spectrum drugs like ethosuximide or carbamazepine are best reserved for specific patterns. Getting the match wrong does not just fail to help; it can worsen seizure control.
Common Side Effects and Cognitive Concerns
Every seizure medication carries side effects, though the type and severity vary widely. Dizziness and drowsiness are among the most common complaints across the board. A network analysis of second- and third-generation drugs found that patients taking eslicarbazepine, perampanel, oxcarbazepine, topiramate, or pregabalin all experienced more dizziness than those on placebo, while perampanel, topiramate, and pregabalin also carried a higher risk of sleepiness.7Scientific Reports. Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis
Cognitive effects are a particular worry for many patients. Topiramate and zonisamide stand out for their association with language difficulties, memory problems, and a general feeling of mental dulling. In one study of zonisamide monotherapy, almost half of the patients reported cognitive complaints after a year, and formal testing confirmed worse performance on word recall, verbal fluency, and certain tasks requiring mental flexibility, with the effects worsening at higher doses.8PubMed. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients Levetiracetam and perampanel, on the other hand, are more associated with irritability and aggressiveness, especially in people who already have a history of behavioral or psychiatric conditions.9PubMed Central. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies Some drugs, including cannabidiol, fenfluramine, and lamotrigine, appear to have neutral or even mildly positive effects on certain aspects of cognition.10PubMed Central. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies
Bone Health Over the Long Term
One side effect that flies under the radar is the impact of seizure medications on bones. Several of the older drugs, particularly phenytoin, carbamazepine, and phenobarbital, speed up the liver enzymes that break down vitamin D, leading to lower levels of the vitamin and, eventually, weaker bones. A study of people with epilepsy found that vitamin D deficiency was present in about 54% of those taking enzyme-inducing drugs, compared with 37% on non-enzyme-inducing drugs.11PubMed Central. Low Vitamin D Levels Are Common in Patients with Epilepsy Chronic users of seizure medications have also been found to have lower bone mineral density than matched controls, with abnormal bone density showing up in about 64% of patients versus 24% of controls in one study.12Arquivos de Neuro-Psiquiatria. Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs
Younger adults may be especially vulnerable. Research on young men taking seizure drugs found that those between ages 25 and 44 lost bone mineral density at the femoral neck at a rate of about 1.8% per year, and that time on medication was one of the strongest predictors of bone loss, even after accounting for other risk factors.13JAMA Neurology. Antiepileptic Drug–Induced Bone Loss in Young Male Patients Who Have Seizures Vitamin D monitoring and supplementation are often recommended for anyone on long-term seizure medication, though the specific approach varies.
Skin Reactions and Genetic Risk
Most rashes from seizure medications are mild and resolve once the drug is stopped, but a small number can escalate into life-threatening reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis, where large areas of skin blister and peel. Aromatic antiepileptic drugs, a chemical family that includes carbamazepine, phenytoin, and lamotrigine, are the most frequent culprits.14PubMed. HLA-associated antiepileptic drug-induced cutaneous adverse reactions
These severe reactions are not random. Certain genetic variants in the immune system, specifically in HLA genes, dramatically increase a person’s risk. The most well-known link is between the HLA-B*15:02 allele, common in many Southeast Asian populations, and carbamazepine-induced Stevens-Johnson syndrome. Pharmacogenomic screening before prescribing is now recommended (and in some places required) for high-risk populations.15PubMed. HLA-associated antiepileptic drug-induced cutaneous adverse reactions A broader review notes that patient characteristics, underlying health conditions, and genetic variations all influence who develops a hypersensitivity reaction.16PubMed. Rashes and other hypersensitivity reactions associated with antiepileptic drugs: A review of current literature
Pregnancy and Seizure Medications
Pregnancy creates a genuine dilemma for women with epilepsy: uncontrolled seizures are dangerous for both mother and fetus, but some medications carry their own risks. Valproate is the most problematic. It is a known human teratogen, linked to roughly a threefold increase in the rate of major birth defects, including spina bifida, cardiac abnormalities, and craniofacial and limb defects, along with a recognizable pattern of features sometimes called “valproate syndrome.”17PubMed. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Despite these well-documented risks, valproate continues to be prescribed to women of childbearing age in many countries, both for epilepsy and for bipolar disorder.18PubMed Central. Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?
Lamotrigine and levetiracetam are generally considered safer options during pregnancy, though no seizure medication is entirely risk-free. Any change in medication during pregnancy should happen under close neurological supervision, ideally before conception, because stopping a drug abruptly can trigger rebound seizures.
Seizure Medications in Older Adults
Epilepsy is surprisingly common in older adults. New-onset seizures in people over 65 are often caused by strokes, brain tumors, or neurodegeneration, and these patients come with their own set of medication challenges. Aging changes how the body absorbs, distributes, and eliminates drugs. Kidney and liver function decline, body composition shifts, and the blood-brain barrier becomes more permeable. All of this means that older adults often end up with higher drug concentrations than younger people on the same dose.19PubMed. Pharmacokinetic considerations about antiseizure medications in the elderly
The practical rule is “start low and go slow.” Reducing loading and maintenance doses of almost all seizure medications is generally recommended for this age group to avoid side effects like falls, confusion, and sedation. Drug interactions are a major concern, too, because older adults often take multiple medications for other conditions. Newer drugs like lamotrigine, levetiracetam, and lacosamide are often preferred in the elderly precisely because they interact with fewer medications than first-generation drugs like phenytoin and carbamazepine.20PubMed. Pharmacokinetic Factors to Consider in the Selection of Antiseizure Drugs for Older Patients with Epilepsy
When Medications Do Not Work
About a third of people with epilepsy do not get adequate seizure control from their first drug. Two leading hypotheses try to explain why. The transporter hypothesis suggests that the brain ramps up production of proteins that pump drugs back out before they can reach their targets. The target hypothesis proposes that the seizure-related changes in the brain alter the drug targets themselves, making them less responsive to the medication.21Brain. Molecular and cellular mechanisms of pharmacoresistance in epilepsy In practice, both mechanisms probably contribute, and the balance likely varies from person to person.
For these patients, combination therapy becomes the next step. The idea behind “rational polytherapy” is to pair drugs that work through different mechanisms, hoping for synergistic effects. In reality, strong evidence for synergy is thin. The only combination with solid clinical data showing true synergism is valproate paired with lamotrigine.22PubMed. Combining antiepileptic drugs–rational polytherapy? Many other combinations are tried based on theoretical reasoning, and epilepsy specialists continue to explore and refine these regimens, but it is honest to say the evidence base for most specific pairings is not yet strong.23Journal of Epilepsy Research. Antiepileptic Drug Therapy in Patients with Drug-Resistant Epilepsy
Cannabidiol as a Seizure Treatment
Pharmaceutical-grade cannabidiol (CBD), sold under the brand name Epidiolex, was approved by the FDA in 2018 for patients two years and older with Dravet syndrome or Lennox-Gastaut syndrome, two severe childhood epilepsies that are notoriously difficult to treat.24PubMed Central. Emerging Use of Epidiolex (Cannabidiol) in Epilepsy A systematic review and meta-analysis of pediatric trials found that CBD treatment was significantly more effective than placebo at reducing seizure frequency, with the odds of at least a 50% seizure reduction roughly two to three times higher depending on the syndrome studied.25PubMed. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis
It is worth being clear about what this is and is not. Epidiolex is a purified, precisely dosed pharmaceutical product, not the CBD oil sold in health food stores. Over-the-counter CBD products vary widely in potency, purity, and actual CBD content, and there is no regulatory framework ensuring they contain what they claim. Using them as a substitute for prescription seizure medication is risky and not supported by the same evidence.
Emergency and Rescue Medications
Some people experience seizure clusters, groups of seizures that come in rapid succession. For these emergencies, fast-acting rescue medications are critical. Benzodiazepines are the mainstay. Rectal diazepam was for years the primary rescue option, but newer delivery methods have expanded the choices significantly. Intranasal midazolam was approved by the FDA in 2019 for people 12 and older, and a nasal spray formulation of diazepam was approved in 2020 for those six and older. Buccal midazolam, placed inside the cheek, is another option available in many countries. These non-rectal routes are easier to administer in public settings and reduce the stigma that sometimes led families to delay using rescue medication.
Herbal Supplements and Dangerous Interactions
Many people with epilepsy use herbal products alongside their prescribed medications, sometimes without telling their doctor. This can be dangerous. Some herbs have their own seizure-promoting properties, and others interact with liver enzymes in ways that change how seizure drugs are processed. Ginkgo biloba, for example, has been shown to ramp up certain liver enzymes, including ones responsible for breaking down phenytoin and valproate, potentially driving blood levels of those drugs below the range needed to prevent seizures.26Journal of Analytical Toxicology. Fatal Seizures Due to Potential Herb-Drug Interactions with Ginkgo Biloba A broader review noted that herbs can alter seizure drug levels through effects on the same cytochrome P450 enzymes and transport proteins, or through contamination with heavy metals.27PubMed. Herbal medicine and epilepsy: proconvulsive effects and interactions with antiepileptic drugs The safest approach is to treat herbal supplements as real drugs and discuss them with a prescriber before combining them with seizure medication.
Stopping Medication After Seizure Freedom
Once a person has been seizure-free for a period, usually at least two years, the question of whether to taper off medication arises. Staying on medication means ongoing side effects and costs; stopping means accepting some risk of seizure return. In one long-term follow-up of patients who discontinued their drugs, the factors most associated with relapse included being 14 or older, having a structural cause for the seizures, and abnormal brain imaging.28PubMed. Discontinuation of antiseizure medications in seizure-free patients with long-term follow-up: Patients’ profile, seizure recurrence, and risk factors
In children with uncomplicated epilepsy, the outlook for successful withdrawal tends to be better. Research has identified the age when seizures first started and the speed of the withdrawal taper as the most important predictors of relapse risk, while factors like family history and earlier EEG results were not significant.29PubMed. Relapse risk analysis after drug withdrawal in epileptic children with uncomplicated seizures Tapering slowly, under medical guidance, reduces the chance of withdrawal seizures and gives time to reverse course if problems arise.
Gene Therapy and the Precision Medicine Frontier
For some of the most severe genetic epilepsies, conventional medications are not enough. Dravet syndrome, caused by mutations in the SCN1A gene, is a case in point. Children with Dravet often respond poorly to standard drugs and face profound developmental consequences. Precision medicine approaches now aim to fix or compensate for the underlying genetic defect rather than just suppressing seizure activity after the fact. Antisense oligonucleotides, short pieces of synthetic genetic material that can boost production of the missing sodium channel, have moved into clinical trials. Gene therapy using viral vectors to deliver corrective genetic instructions directly to the brain has also shown promising results in animal models.30Neurotherapeutics. Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy CRISPR-based technologies that activate the SCN1A gene without cutting the DNA are in earlier stages of development but represent another avenue under active investigation.31PubMed Central. Targeted Molecular Strategies for Genetic Neurodevelopmental Disorders: Emerging Lessons from Dravet Syndrome
Meanwhile, a synthetic neurosteroid called ganaxolone has shown potential in Angelman syndrome, a rare neurogenetic condition with prominent seizures and developmental delay. In mouse models, ganaxolone reduced seizures, improved motor function, and even recovered some spatial memory deficits, all without the effects wearing off over a four-week treatment period.32PubMed. Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model These targeted therapies are still in relatively early stages, but they signal a shift from one-size-fits-all seizure suppression toward treatments designed for specific genetic causes.
Access and Affordability Around the World
The medications discussed in this article are widely available in high-income countries, but the picture looks very different globally. More than 80% of people with epilepsy live in middle- and low-income countries, where most of the population lacks reliable access to seizure medications. This contributes to a large treatment gap, meaning millions of people who could benefit from treatment simply do not receive it. Making matters worse, average retail prices for seizure drugs are not significantly different across countries, even though per capita income varies enormously.33PubMed Central. Survey on the worldwide availability and affordability of antiseizure medications: Report of the ILAE Task Force on Access to Treatment A month’s supply of lamotrigine or levetiracetam may represent a manageable pharmacy expense in Western Europe but a prohibitive cost for a family in sub-Saharan Africa. The gap is not primarily one of medical knowledge or drug development. It is one of economics and infrastructure.